Ever since this story came out the stock has been muted, and ticking down. Rather complicated for the company from the PR angle, the studies (evidence, or lack of here), intellectual property of the product. But one thing is for sure, it does not matter to some whether the product is safe after/when they hear that one of the chemicals had negative affects in mice, they are out.
seems like every time they get a nice bump, there is some analyst there to downgrade whatever catalyst there is. Last time it was Wells Fargo.
I just checked around and found nothing other that some "free" analyst note - I did not feel like registering. Guess it's just a technical haircut, or I'll have to find out after the fact.
Not a big time investor here, but use their plan, which I wish was more user friendly.
Last month I switched my plan off as the stock was nearing the high 140's, but then one week I saw the stock dive due to the biotech sell off, so I tried turning the plan back on to take advantage of the dip. (I like the automatic purchase as far as purchasing small incremental amounts without getting charged an arm and leg in commissions. With recurring automatic purchase though, you can't purchase on the fly.)
It seems like if you want to use the recurring optional automatic investment, one has to give it 15 days to set the ball rolling - like a probation period.
I was looking to purchase some around 136 now the price is nearing 143. I'll probably end up around 146-150 on the 15th of the month when my purchase goes thru. I doubt I will be trying to time any more purchases thru this plan :(
I have been holding this since '92. Very frustrating. I think all the analysts give MRO the thumbs up, but the institutions/market just favors the other producers, like OXY, APA. This is a slow mover, zigzagging slowly upward.
We will see how the intend to continue growing into the future. I think the margins are really low in the oil/tar sands, but then you don't have the exploration costs. The CEO seems to favor a higher growth rate.